nach oben

Clinical and Translational Oncology

Erschienen in:

21.08.2023 | RESEARCH ARTICLE

Proteomics-based clustering of lung adenocarcinoma identifies three subtypes with significantly different clinical and molecular features

verfasst von: Rongzhuo Long, Nayila Abulimiti, Xiaosheng Wang

Erschienen in: Clinical and Translational Oncology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Lung adenocarcinoma (LUAD) is a predominant subtype of lung cancer. Although molecular classification of LUAD has been widely explored, proteomics-based subtyping of LUAD remains scarce.

Methods

We proposed a subtyping method for LUAD based on the expression profiles of 500 proteins with the largest expression variability across LUAD. Furthermore, we comprehensively compared molecular and clinical features among the LUAD subtypes.

Results

Consensus clustering identified three subtypes of LUAD, namely MtE, DrE, and StE. We demonstrated this subtyping method to be reproducible by analyzing two independent LUAD cohorts. MtE was characterized by high enrichment of metabolic pathways, high EGFR mutation rate, low stemness, proliferation, invasion, metastasis and inflammation signatures, favorable prognosis; DrE was characterized by high enrichment of DNA repair pathways, high TP53 mutation rate, and high levels of genomic instability, stemness, proliferation, and intratumor heterogeneity (ITH); and StE was characterized by high enrichment of stroma-related pathways, high KRAS mutation rate, and low levels of genomic instability.

Conclusions

The proteomics-based clustering analysis identified three LUAD subtypes with significantly different molecular and clinical properties. The novel subtyping method offers new perspectives on the cancer biology and holds promise in improving the clinical management of LUAD.

Nur mit Berechtigung zugänglich

Huang J, Deng Y, Tin MS, Lok V, Ngai CH, Zhang L, et al. Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: a global analysis. Chest. 2022;161(4):1101–11.https://doi.org/10.1016/j.chest.2021.12.655CrossRefPubMed

Xia C, Dong X, Li H, Cao M, Sun D, He S, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J. 2022;135(05):584–90.https://doi.org/10.1097/CM9.0000000000002108CrossRefPubMedPubMedCentral

Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.https://doi.org/10.1038/nrc3775CrossRefPubMedPubMedCentral

Tavernari D, Battistello E, Dheilly E, Petruzzella AS, Mina M, Sordet-Dessimoz J, et al. Nongenetic evolution drives lung adenocarcinoma spatial heterogeneity and progressionnongenetic evolution of lung adenocarcinoma heterogeneity. Cancer Discov. 2021;11(6):1490–507.https://doi.org/10.1158/2159-8290.CD-20-1274CrossRefPubMed

Li WY, Zhao TT, Xu HM, Wang ZN, Xu YY, Han Y, et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):145.https://doi.org/10.1186/s12885-019-5331-zCrossRefPubMedPubMedCentral

Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511(7511):543.https://doi.org/10.1038/nature13385CrossRef

Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, et al. Proteogenomic characterization reveals therapeutic vulnerabilities in lung adenocarcinoma. Cell. 2020;182(1):200–25.https://doi.org/10.1016/j.cell.2020.06.013CrossRefPubMedPubMedCentral

Liu Q, Lei J, Zhang X, Wang X. Classification of lung adenocarcinoma based on stemness scores in bulk and single cell transcriptomes. Comput Struct Biotechnol J. 2022;20:1691–701.https://doi.org/10.1016/j.csbj.2022.04.004CrossRefPubMedPubMedCentral

Menyhárt O, Győrffy B. Multi-omics approaches in cancer research with applications in tumor subtyping, prognosis, and diagnosis. Comput Struct Biotechnol J. 2021;19:949–60.https://doi.org/10.1016/j.csbj.2021.01.009CrossRefPubMedPubMedCentral

10.

Yaffe MB. Why geneticists stole cancer research even though cancer is primarily a signaling disease. Sci Signal. 2019. https://doi.org/10.1126/scisignal.aaw3483.CrossRefPubMed

11.

Macklin A, Khan S, Kislinger T. Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. Clin Proteomics. 2020;17:17.https://doi.org/10.1186/s12014-020-09283-wCrossRefPubMedPubMedCentral

12.

Gry M, Rimini R, Strömberg S, Asplund A, Pontén F, Uhlén M, et al. Correlations between RNA and protein expression profiles in 23 human cell lines. BMC Genomics. 2009;10(1):1–14.https://doi.org/10.1186/1471-2164-10-365CrossRef

13.

Xu J-Y, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, et al. Integrative proteomic characterization of human lung adenocarcinoma. Cell. 2020;182(1):245–61.https://doi.org/10.1016/j.cell.2020.05.043CrossRefPubMed

14.

Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7.https://doi.org/10.1186/1471-2105-14-7CrossRefPubMedPubMedCentral

15.

Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9(1):1–13.https://doi.org/10.1186/1471-2105-9-559CrossRef

16.

Bland JM, Altman DG. Survival probabilities (the Kaplan-Meier method). BMJ. 1998;317(7172):1572.https://doi.org/10.1136/bmj.317.7172.1572CrossRefPubMedPubMedCentral

17.

Li M, Zhang Z, Li L, Wang X. An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles. Commun Biol. 2020;3(1):505.https://doi.org/10.1038/s42003-020-01230-7CrossRefPubMedPubMedCentral

18.

Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc. 1995;57(1):289–300.https://doi.org/10.1111/j.2517-6161.1995.tb02031.xCrossRef

19.

Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019;47(W1):W191–8.https://doi.org/10.1093/nar/gkz369CrossRefPubMedPubMedCentral

20.

Sullivan I, Planchard D. Next-Generation EGFR tyrosine kinase inhibitors for treating EGFR-mutant lung cancer beyond first line. Front Med (Lausanne). 2016;3:76.https://doi.org/10.3389/fmed.2016.00076CrossRefPubMed

21.

Li W-Y, Zhao T-T, Xu H-M, Wang Z-N, Xu Y-Y, Han Y, et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC Cancer. 2019;19(1):1–9.https://doi.org/10.1186/s12885-019-5331-zCrossRef

22.

Wang X, Sun Q. TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 2017;8(1):624–43.https://doi.org/10.18632/oncotarget.13483CrossRefPubMed

23.

Ferguson LR, Chen H, Collins AR, Connell M, Damia G, Dasgupta S, et al. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition. Seminars Cancer Biol. 2015. https://doi.org/10.1016/j.semcancer.2015.03.005.CrossRef

24.

Palmieri G, Colombino M, Cossu A, Marchetti A, Botti G, Ascierto PA. Genetic instability and increased mutational load: which diagnostic tool best direct patients with cancer to immunotherapy? J Transl Med. 2017;15(1):17.https://doi.org/10.1186/s12967-017-1119-6CrossRefPubMedPubMedCentral

25.

Storchova Z, Pellman D. From polyploidy to aneuploidy, genome instability and cancer. Nat Rev Mol Cell Biol. 2004;5(1):45–54.https://doi.org/10.1038/nrm1276CrossRefPubMed

26.

Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria J-C. The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol. 2012;9(3):144–55.https://doi.org/10.1038/nrclinonc.2012.3CrossRefPubMed

27.

Ayob AZ, Ramasamy TS. Cancer stem cells as key drivers of tumour progression. J Biomed Sci. 2018;25(1):20.https://doi.org/10.1186/s12929-018-0426-4CrossRefPubMedPubMedCentral

28.

Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338–345.https://doi.org/10.1038/nature12625CrossRefPubMed

29.

Clayton NS, Ridley AJ. Targeting Rho GTPase signaling networks in cancer. Front Cell Dev Biol. 2020;8:222.https://doi.org/10.3389/fcell.2020.00222CrossRefPubMedPubMedCentral

30.

Inamura K. Lung cancer: understanding its molecular pathology and the 2015 WHO classification. Front Oncol. 2017;7:193.https://doi.org/10.3389/fonc.2017.00193CrossRefPubMedPubMedCentral

31.

Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W, et al. Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res. 2012;31(1):70.https://doi.org/10.1186/1756-9966-31-70CrossRefPubMedPubMedCentral

32.

Duan S, Huang W, Liu X, Liu X, Chen N, Xu Q, et al. IMPDH2 promotes colorectal cancer progression through activation of the PI3K/AKT/mTOR and PI3K/AKT/FOXO1 signaling pathways. J Exp Clin Cancer Res. 2018;37(1):304.https://doi.org/10.1186/s13046-018-0980-3CrossRefPubMedPubMedCentral

33.

He Y, Zheng Z, Xu Y, Weng H, Gao Y, Qin K, et al. Over-expression of IMPDH2 is associated with tumor progression and poor prognosis in hepatocellular carcinoma. Am J Cancer Res. 2018;8(8):1604–14.PubMedPubMedCentral

34.

Liu X, Sato N, Yabushita T, Li J, Jia Y, Tamura M, et al. IMPDH inhibition activates TLR-VCAM1 pathway and suppresses the development of MLL-fusion leukemia. EMBO Mol Med. 2023;15(1):e15631.https://doi.org/10.15252/emmm.202115631CrossRefPubMed

35.

Huang F, Huffman KE, Wang Z, Wang X, Li K, Cai F, et al. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. J Clin Invest. 2021. https://doi.org/10.1172/JCI139929.CrossRefPubMedPubMedCentral

36.

Huang F, Ni M, Chalishazar MD, Huffman KE, Kim J, Cai L, et al. Inosine monophosphate dehydrogenase dependence in a subset of small cell lung cancers. Cell Metab. 2018;28(3):369–82.https://doi.org/10.1016/j.cmet.2018.06.005CrossRefPubMedPubMedCentral

Titel: Proteomics-based clustering of lung adenocarcinoma identifies three subtypes with significantly different clinical and molecular features
verfasst von: Rongzhuo Long
Nayila Abulimiti
Xiaosheng Wang
Publikationsdatum: 21.08.2023
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 2/2024
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03275-6

Springer Medizin

Proteomics-based clustering of lung adenocarcinoma identifies three subtypes with significantly different clinical and molecular features

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Is surgical indication in multiple myeloma a poor prognosis sign? SEER database analysis

Mechanism of action and treatment of type I interferon in hepatocellular carcinoma

LINC00844 suppresses tumor progression and predicts survival outcomes through inhibiting miR-19a-5p in cholangiocarcinoma

Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators

The role of sex and gender in the diagnosis and treatment of lung cancer: the 6th ICAPEM Annual Symposium

Correction to: Efficacy and safety of trifluridine/tipiracil (TAS‑102) in patients with metastatic colorectal cancer: a systematic review and meta‑analysis

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie